- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Cadherin-17 as a target for the immunoPET of adenocarcinoma ; day:16 ; month:4 ; year:2024 ; pages:1-11
European journal of nuclear medicine and molecular imaging ; (16.4.2024), 1-11
- Creator
-
Delaney, Samantha
Keinänen, Outi
Lam, Dennis
Wolfe, Andrew L.
Hamakubo, Takao
Zeglis, Brian M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-024-06709-7
- URN
-
urn:nbn:de:101:1-2406282104161.316205011921
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Delaney, Samantha
- Keinänen, Outi
- Lam, Dennis
- Wolfe, Andrew L.
- Hamakubo, Takao
- Zeglis, Brian M.
- SpringerLink (Online service)
Other Objects (12)
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example
(Immuno)proteasomes as therapeutic target in acute leukemia
ImmunoPET imaging of TIGIT in the glioma microenvironment
Guidelines on lung adenocarcinoma prognosis based on immuno-glycolysis-related genes
Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications
Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET
Immuno-oncology
Immuno-Oncology
ImmunoMedicine
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example
(Immuno)proteasomes as therapeutic target in acute leukemia
ImmunoPET imaging of TIGIT in the glioma microenvironment
Guidelines on lung adenocarcinoma prognosis based on immuno-glycolysis-related genes
Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications
Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET
Immuno-oncology
Immuno-Oncology
ImmunoMedicine
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example
(Immuno)proteasomes as therapeutic target in acute leukemia
ImmunoPET imaging of TIGIT in the glioma microenvironment
Guidelines on lung adenocarcinoma prognosis based on immuno-glycolysis-related genes
Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications
Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET
Immuno-oncology
Immuno-Oncology